Matasar, Matthew J.

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 94

Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).

Sauter, C. S., Riviere, I., Bernal, Y., Wang, X., Purdon, T., Yoo, S., Moskowitz, C. H., Giralt, S., Matasar, M. J., Curran, K. J., et al. (2015) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 36

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Intlekofer, A. M., Joffe, E., Batlevi, C. L., Hilden, P., He, J., Seshan, V. E., Zelenetz, A. D., Palomba, M. L., Moskowitz, C. H., Portlock, C., et al. (2018) · Blood Cancer Journal

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 35